---
id: nccn-thyroid-2025
title: "NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma"
short_title: "Thyroid Cancer"
organization: National Comprehensive Cancer Network
country: United States
url: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1467
specialty: oncology
guideline_type: clinical-practice
evidence_system: nccn
conditions:
  - Thyroid Cancer
  - Papillary Thyroid Carcinoma
  - Follicular Thyroid Carcinoma
  - Medullary Thyroid Carcinoma
  - Anaplastic Thyroid Carcinoma
tags:
  - thyroid cancer
  - differentiated thyroid cancer
  - RAI
  - thyroidectomy
publication_date: 2025-01-15
previous_version_date: 2024-01-20
status: current
supersedes: nccn-thyroid-2024
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the diagnosis, treatment, and surveillance of thyroid carcinoma across all histologic subtypes.

## Key Recommendations

### Differentiated Thyroid Cancer (DTC) - Papillary/Follicular
**Surgery:**
- Lobectomy for low-risk unifocal tumors <4cm
- Total thyroidectomy for tumors >4cm, multifocal, extrathyroidal extension, nodal metastases

**Risk Stratification (ATA):**
- Low risk: Intrathyroidal, no vascular invasion, complete resection
- Intermediate risk: Minor extrathyroidal extension, aggressive histology, vascular invasion
- High risk: Gross extrathyroidal extension, incomplete resection, distant metastases

**Radioactive Iodine (RAI):**
- Not routine for low-risk DTC
- Consider for intermediate-risk
- Recommended for high-risk disease

**TSH Suppression:**
- High-risk: TSH <0.1 mU/L
- Intermediate-risk: TSH 0.1-0.5 mU/L
- Low-risk (disease-free): TSH lower-normal

### Medullary Thyroid Carcinoma (MTC)
- Total thyroidectomy + central lymph node dissection
- RET mutation testing (germline and somatic)
- Calcitonin and CEA monitoring
- Kinase inhibitors (vandetanib, cabozantinib, selpercatinib) for advanced/metastatic

### Anaplastic Thyroid Carcinoma (ATC)
- Rapidly fatal without treatment
- BRAF/MEK inhibitors (dabrafenib/trametinib) for BRAF V600E mutant
- Combined modality therapy (surgery, radiation, chemo) when feasible
- Clinical trial enrollment encouraged

### Advanced/Metastatic DTC
- Lenvatinib or sorafenib for RAI-refractory DTC
- NTRK inhibitors if NTRK fusion positive
- RET inhibitors if RET fusion positive

### Surveillance
- Thyroglobulin (DTC), calcitonin/CEA (MTC) monitoring
- Neck ultrasound
- Cross-sectional imaging per risk
